MDM2 Inhibitor AMG-232 (KRT-232) and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects of MDM2 inhibitor AMG-232 (KRT-232) and
radiation therapy in treating patients with soft tissue sarcoma. MDM2 inhibitor AMG-232
(KRT-232) may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth. Giving MDM2 inhibitor AMG-232 (KRT-232) and radiation therapy before surgery may make
the tumor smaller and reduce the amount of normal tissue that needs to be removed.